BACKGROUND: The Corheart 6, a novel fully magnetically levitated ventricular assist device (VAD), represents a breakthrough in miniaturized mechanical circulatory support technology. Notably smaller than the internationally recognized Heartmate 3, Corheart 6 has shown promise in addressing advanced heart failure. This abstract presents a single-center experience with 20 successful Corheart 6 implantations since October 2021.
METHODS: A retrospective analysis was conducted on 20 patients who underwent Corheart 6 implantation at our center. Procedural details, patient demographics, and postoperative outcomes were systematically documented to assess the efficacy and safety of this miniaturized VAD. The Corheart 6's unique design and fully magnetically levitated technology were leveraged for optimal patient selection and successful implantation.
RESULTS: The 20 cases of Corheart 6 implantation demonstrated favorable outcomes. The device, being smaller in size compared to Heartmate 3, showcased effective hemodynamic support. Postoperative assessments revealed improved cardiac function, increased exercise tolerance, and enhanced overall quality of life for the patients. Importantly, no device-related complications were reported during the follow-up period.CONCLUSIONS:Corheart 6, as a fully magnetically levitated miniaturized VAD, has proven to be a successful option in our single-center experience. Its smaller size and innovative design contribute to favorable outcomes, making it a promising alternative to established devices. The absence of device-related complications underscores the safety profile of Corheart 6. Further multi-center studies and extended follow-up are warranted to confirm and broaden the applicability of Corheart 6 as a valuable tool in the management of advanced heart failure.
